SOE Management Agency Urges Bio Farma to Return to Original Mandate: Developing Own Vaccines
The State-Owned Enterprise (SOE) Management Agency and Danantara are encouraging PT Bio Farma (Persero) to strengthen its primary mandate in vaccine research and development, while simultaneously expanding the market for Indonesian healthcare products to a global level.
During a meeting with the Board of Directors of the Bio Farma Group on Monday (14/09/2026), the Head of the SOE Management Agency and Chief Operating Officer (COO) of Danantara, Dony Oskaria, stated that Bio Farma’s transformation needs to be directed towards re-strengthening the company’s ability to create and develop its own products, rather than merely acting as a manufacturer for other companies’ vaccines.
“In essence, Bio Farma’s mandate is to produce vaccines. However, for a long time, there has been no addition of new products. Consequently, they have become a factory for other people’s vaccines. Now, we want to restore that,” said Dony.
This strengthening of research and development aligns with the expansion of Bio Farma’s products and technology into international markets. Over the past two years, technology developed in Indonesia has been introduced to several countries, including Senegal, Ghana, and India.
Moving forward, Bio Farma is also being directed to expand its product range to several countries in the African region, as part of efforts to strengthen Indonesia’s position as one of the global producers of vaccines and healthcare products.
This step is part of Bio Farma’s transformation to bolster research and development (R&D) capabilities, generate new products, and increase the competitiveness of the Indonesian healthcare industry in the global market.
By refocusing on research and development, Bio Farma is expected not only to become more capable of creating its own healthcare products but also to strengthen national health independence and resilience. At the same time, the mastery of Indonesian-originated healthcare technology and products is expected to continue expanding, thereby providing a greater contribution to the global healthcare industry.
Source: jawawa.id (https://jawawa.id/newsitem/soe-management-agency-urges-bio-farma-to-return-to-original-mandate-developing-own-vaccines-1789549156)
Originally published by CNBC Indonesia (https://www.cnbcindonesia.com/market/20260916125147-17-768346/bp-bumn-dorong-bio-farma-kembali-ke-mandat-awal-bikin-vaksin-sendiri), translated from Indonesian